Full Description
This open access book reflects on matters of social and ethical concern raised in the daily practices of those working in and around precision oncology. Each chapter addresses the experiences, concerns and issues at stake for people who work in settings where precision oncology is practiced, enacted, imagined or discussed. It subsequently discusses and analyses bioethical dilemmas, scientific challenges and economic trade-offs, the need for new policies, further technological innovation, social work, as well as phenomenological research.
This volume takes a broad actor-centred perspective as, whenever cancer is present, the range of actors with issues at stake appears almost unlimited. This perspective and approach opens up the possibility for further in-depth and diverse questions, posed by the actors themselves, such as: How are cancer researchers navigating biological uncertainties? How do clinicians and policy-makers address ethical dilemmas around prioritisationof care? What are the patients' experiences with, and hopes for, precision oncology? How do policy-makers and entrepreneurs envisage precision oncology? These questions are of great interest to a broad audience, including cancer researchers, oncologists, policy-makers, medical ethicists and philosophers, social scientists, patients and health economists.
Contents
Introduction (Anne Bremer and Roger Strand).- Chapter 1. Precision oncology in the news (Mille Stenmarck and Irmelin Nilsen).- Chapter 2. Cancer biomarkers from a patient's perspective (Karen Gissum).- Chapter 3. Breast cancer: reconstruction of trouble (Hanna Dillekås).- Chapter 4. HER2: an apparently 'simple' biomarkers revealing the complexities and uncertainties of precision oncology (Elisabeth Wik, Anne Bremer and Lars A. Akslen).- Chapter 5. Integrating genomic and non-genomic factors in shaping the personal fingerprint in personalised cancer treatments (Mariano Bizzari and Andrea Pensotti).- Chapter 6. Systems medicine and perspectives on precision oncology (Rune Kleppe, Inge Jonassen and Roger Strand).- Chapter 7. Precision oncology: the challenges related to publishing (Maria Lie Lotsberg).- Chapter 8. Filled with Desire, Perceive Molecules (Caroline Engen and Roger Strand).- Chapter 9. Precision health and ethical ambiguity: How much cancer can we afford to prevent? (Leonard Fleck).- Chapter 10. New cancer drugs and the public controversy: how can biomarkers contribute? (Eirik Tranvåg and Roger Strand).- Chapter 11. Assessing the cost-effectiveness of targeted therapies and checkpoint inhibitors (John Cairns).- Chapter 12. Real-world data in Health Technology Assessment of targeted cancer therapy (Jiyeon Kang).- Chapter 13. Negotiating safety and resources in a first in human cancer trial in Denmark (Line Hillersdal).- Conclusion: Precision oncology: Fact or fantasy? (Roger Strand and Anne Bremer).
